Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
12 05 2020
Historique:
pubmed: 11 4 2020
medline: 8 6 2021
entrez: 11 4 2020
Statut: ppublish

Résumé

This study aimed to compare echocardiographic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). The PARTNER 3 trial (Placement of Aortic Transcatheter Valves) randomized 1000 patients with severe aortic stenosis and low surgical risk to undergo either transfemoral TAVR with the balloon-expandable SAPIEN 3 valve or SAVR. Transthoracic echocardiograms obtained at baseline and at 30 days and 1 year after the procedure were analyzed by a consortium of 2 echocardiography core laboratories. The percentage of moderate or severe aortic regurgitation (AR) was low and not statistically different between the TAVR and SAVR groups at 30 days (0.8% versus 0.2%; In patients with severe aortic stenosis and low surgical risk, TAVR with the SAPIEN 3 valve was associated with similar percentage of moderate or severe AR compared with SAVR but higher percentage of mild AR. Transprosthetic gradients, valve areas, percentage of severe prosthesis-patient mismatch, and left ventricular mass regression were similar in TAVR and SAVR. SAVR was associated with significant deterioration of right ventricular systolic function and greater tricuspid regurgitation, which persisted at 1 year. High Z

Sections du résumé

BACKGROUND
This study aimed to compare echocardiographic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
METHODS
The PARTNER 3 trial (Placement of Aortic Transcatheter Valves) randomized 1000 patients with severe aortic stenosis and low surgical risk to undergo either transfemoral TAVR with the balloon-expandable SAPIEN 3 valve or SAVR. Transthoracic echocardiograms obtained at baseline and at 30 days and 1 year after the procedure were analyzed by a consortium of 2 echocardiography core laboratories.
RESULTS
The percentage of moderate or severe aortic regurgitation (AR) was low and not statistically different between the TAVR and SAVR groups at 30 days (0.8% versus 0.2%;
CONCLUSIONS
In patients with severe aortic stenosis and low surgical risk, TAVR with the SAPIEN 3 valve was associated with similar percentage of moderate or severe AR compared with SAVR but higher percentage of mild AR. Transprosthetic gradients, valve areas, percentage of severe prosthesis-patient mismatch, and left ventricular mass regression were similar in TAVR and SAVR. SAVR was associated with significant deterioration of right ventricular systolic function and greater tricuspid regurgitation, which persisted at 1 year. High Z

Identifiants

pubmed: 32272848
doi: 10.1161/CIRCULATIONAHA.119.044574
doi:

Banques de données

ClinicalTrials.gov
['NCT02675114']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1527-1537

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Auteurs

Philippe Pibarot (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Erwan Salaun (E)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Abdellaziz Dahou (A)

Cardiovascular Research Foundation, New York, NY (A.D., E.A., M.C.A., M.B.L., R.T.H.).

Eleonora Avenatti (E)

Cardiovascular Research Foundation, New York, NY (A.D., E.A., M.C.A., M.B.L., R.T.H.).

Ezequiel Guzzetti (E)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Mohamed-Salah Annabi (MS)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Oumhani Toubal (O)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Mathieu Bernier (M)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Jonathan Beaudoin (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Géraldine Ong (G)

St Michael's Hospital, University of Toronto, Canada (G.O.).

Julien Ternacle (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Laura Krapf (L)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada (P.P., E.S., E.G., M.-S.A., O.T., M.B., J.B., J.T., L.K.).

Vinod H Thourani (VH)

Department of Cardiovascular Surgery, Piedmont Heart Institute, Atlanta, GA (V.H.T.).

Raj Makkar (R)

Cedars-Sinai Medical Center, Los Angeles, CA (R.M.).

Susheel K Kodali (SK)

Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York (S.K.K., M.C.A., C.R.S., M.B.L., R.T.H.).

Mark Russo (M)

Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (M.R.).

Samir R Kapadia (SR)

Cleveland Clinic, OH (S.R.K.).

S Chris Malaisrie (SC)

Feinberg School of Medicine, Northwestern University, Chicago, IL (S.C.M.).

David J Cohen (DJ)

University of Missouri-Kansas City (D.J.C.).

Jonathon Leipsic (J)

St Paul's Hospital, Vancouver, Canada (J.L., P.B., J.G.W.).

Philipp Blanke (P)

St Paul's Hospital, Vancouver, Canada (J.L., P.B., J.G.W.).

Mathew R Williams (MR)

NYU-Langone Medical Center, New York, NY (M.R.W.).

James M McCabe (JM)

University of Washington, Seattle (J.M.M.).

David L Brown (DL)

Baylor Scott & White Healthcare, Plano, TX (D.L.B., M.J.M.).

Vasilis Babaliaros (V)

Emory University School of Medicine, Atlanta, GA (V.B.).

Scott Goldman (S)

Lankenau Medical Center, Wynnewood, PA (S.G.).

Wilson Y Szeto (WY)

University of Pennsylvania, Philadelphia (W.Y.S.).

Philippe Généreux (P)

Gagnon Cardiovascular Institute, Morristown Medical Center, NJ (P.G.).

Ashish Pershad (A)

Banner University Medical Center, Phoenix, AZ (A.P.).

Maria C Alu (MC)

Cardiovascular Research Foundation, New York, NY (A.D., E.A., M.C.A., M.B.L., R.T.H.).
Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York (S.K.K., M.C.A., C.R.S., M.B.L., R.T.H.).

Ke Xu (K)

Edwards Lifesciences, Irvine, CA (K.X., E.R.).

Erin Rogers (E)

Edwards Lifesciences, Irvine, CA (K.X., E.R.).

John G Webb (JG)

St Paul's Hospital, Vancouver, Canada (J.L., P.B., J.G.W.).

Craig R Smith (CR)

Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York (S.K.K., M.C.A., C.R.S., M.B.L., R.T.H.).

Michael J Mack (MJ)

Baylor Scott & White Healthcare, Plano, TX (D.L.B., M.J.M.).

Martin B Leon (MB)

Cardiovascular Research Foundation, New York, NY (A.D., E.A., M.C.A., M.B.L., R.T.H.).
Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York (S.K.K., M.C.A., C.R.S., M.B.L., R.T.H.).

Rebecca T Hahn (RT)

Cardiovascular Research Foundation, New York, NY (A.D., E.A., M.C.A., M.B.L., R.T.H.).
Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York (S.K.K., M.C.A., C.R.S., M.B.L., R.T.H.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH